Minerva Neurosciences Inc - Asset Resilience Ratio
Minerva Neurosciences Inc (NERV) has an Asset Resilience Ratio of 0.30% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Minerva Neurosciences Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Minerva Neurosciences Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Minerva Neurosciences Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Minerva Neurosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Minerva Neurosciences Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $100.00K | 0.3% |
| Total Liquid Assets | $100.00K | 0.30% |
Asset Resilience Insights
- Limited Liquidity: Minerva Neurosciences Inc maintains only 0.30% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Minerva Neurosciences Inc Industry Peers by Asset Resilience Ratio
Compare Minerva Neurosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Minerva Neurosciences Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Minerva Neurosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.27% | $100.00K | $37.14 Million | +0.09pp |
| 2023-12-31 | 0.18% | $100.00K | $56.90 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $57.63 Million | -- |
| 2019-12-31 | 31.54% | $24.44 Million | $77.50 Million | +4.40pp |
| 2018-12-31 | 27.14% | $37.76 Million | $139.14 Million | -28.44pp |
| 2017-12-31 | 55.59% | $102.11 Million | $183.70 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $132.94 Million | -- |
| 2015-12-31 | 21.70% | $17.92 Million | $82.58 Million | +21.65pp |
| 2014-12-31 | 0.05% | $35.00K | $68.45 Million | -- |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble r… Read more